港股异动丨昊海生物科技(6826.HK)涨逾5% 耗资749.4万港元回购11万股
格隆汇5月17日丨昊海生物科技(6826.HK)涨逾5%,报71.85港元;昊海生科(688366.SH)亦涨约5%,报145.48元。昊海生物科技(06826.HK)发布公告,2021年5月14日耗资749.4万港元回购11万股,每股价格为66.8-69.5港元。昊海生科发布关于对上海证券交易所2020年年度报告问询函的回复公告称,在白内障领域,公司已初步完成眼科粘弹剂、人工晶状体产品的全产业链布局,在眼科领域,公司致力于成为专业的眼科产品解决方案提供商。在医疗美容与创面护理领域,公司将加强“海薇”、“姣兰”、“海魅”三款玻尿酸产品的销售推广,积极推进第四代有机交联玻尿酸等产品研发工作,巩固和强化公司在真皮填充剂产品领域的竞争优势等。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.